Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

Kevin C. O'Boyle net worth and biography

Kevin O'Boyle Biography and Net Worth

Director of Nevro

Kevin O'Boyle has served on our Board since March 2019. Mr. O’Boyle has over 20 years of executive management experience in the medical device industry. Mr. O’Boyle currently serves as a director of GenMark Diagnostics, Inc. and Sientra, Inc. Previously, Mr. O’Boyle served as Senior Vice President and Chief Financial Officer of Advanced Biohealing Inc. a medical device company, from December 2010 until it was acquired in July 2011. Mr. O’Boyle served as CFO of NuVasive, Inc. from January 2003 until December 2009. Prior to that, Mr. O’Boyle served in various leadership positions during his six years with ChromaVision Medical Systems, Inc. Mr. O’Boyle received a B.S. in Accounting from the Rochester Institute of Technology and completed the Executive Management Program at the University of California Los Angeles, John E. Anderson Graduate Business School.

What is Kevin C. O'Boyle's net worth?: The estimated net worth of Kevin C. O'Boyle is at least $1.28 million as of August 16th, 2019. Mr. O'Boyle owns 102,112 shares of Nevro stock worth more than $1,275,379 as of April 16th. This net worth approximation does not reflect any other investments that Mr. O'Boyle may own. Learn More about Kevin C. O'Boyle's net worth.
How do I contact Kevin C. O'Boyle?: The corporate mailing address for Mr. O'Boyle and other Nevro executives is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. Nevro can also be reached via phone at (650) 251-0005 and via email at [email protected]. Learn More on Kevin C. O'Boyle's contact information.
Has Kevin C. O'Boyle been buying or selling shares of Nevro?: Kevin C. O'Boyle has not been actively trading shares of Nevro during the past quarter. Most recently, on Tuesday, December 14th, Kevin C. Oboyle bought 2,400 shares of Nevro stock. The stock was acquired at an average cost of $83.78 per share, with a total value of $201,072.00. Learn More on Kevin C. O'Boyle's trading history.
Who are Nevro's active insiders?: Nevro's insider roster includes Michael DeMane (Director), D. Grossman (CEO), Kevin O'Boyle (Director), Kashif Rashid (General Counsel), and Elizabeth Weatherman (Director). Learn More on Nevro's active insiders.
Are insiders buying or selling shares of Nevro?: During the last twelve months, Nevro insiders bought shares 1 times. They purchased a total of 7,500 shares worth more than $171,600.00. The most recent insider tranaction occured on June, 7th when Director Shawn Mccormick bought 7,500 shares worth more than $171,600.00. Insiders at Nevro own 3.0% of the company. Learn More about insider trades at Nevro.
Information on this page was last updated on 6/7/2023.

Kevin C. O'Boyle Insider Trading History at Nevro

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/14/2021	Buy	2,400	$83.78	$201,072.00
6/5/2019	Buy	1,675	$60.00	$100,500.00

Kevin C. O'Boyle Buying and Selling Activity at Nevro

Nevro Company Overview

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

Today's Range

Now: $12.49

$12.35

$13.06

50 Day Range

MA: $14.90

$12.73

$17.61

2 Week Range

Now: $12.49

$12.34

$39.67

Volume

357,354 shs

Average Volume

476,898 shs

Market Capitalization

$454.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Bitcoin Rockets To Record High But Buy THIS Instead

From Paradigm Press | Ad